JAZZ Q2 2020 Earnings — Jazz Pharmaceuticals plc Revenue & Financial Results | Market Cap Arena

JAZZJazz Pharmaceuticals plc

$11B

Q2 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$562M+5.3% YoY

Gross Profit

$534M95.0% margin

Operating Income

$198M35.2% margin

Net Income

$115M20.4% margin

EPS (Diluted)

$2.06

QoQ Revenue Growth

+5.2%

Cash Flow

Operating Cash Flow

$183M

Free Cash Flow

$77M

Stock-Based Comp.

$31M

Balance Sheet

Total Assets

$6.1B

Total Liabilities

$2.9B

Stockholders' Equity

$3.1B

Cash & Equivalents

$786M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$562M	$534M	+5.3%
Gross Profit	$534M	$506M	+5.5%
Operating Income	$198M	$204M	-3.0%
Net Income	$115M	$262M	-56.2%

Revenue Segments

Product And Services, Product Sales

$558M50%

Xyrem

$447M40%

Defitelio/Defibrotide

$43M4%

Erwinaze And Erwinase

$33M3%

Vyxeos

$27M2%

Sunosi

$9M1%

Product And Services, Royalties And Contract Revenue

$4M0%

Other Products

$852,0000%

Geographic Segments

UNITED STATES

$516M92%

Europe

$38M7%

Other Countries

$8M2%